Literature DB >> 6610328

Plasma catecholamines in pheochromocytoma: effect of urographic contrast media.

J Raisanen, B Shapiro, G M Glazer, S Desai, J C Sisson.   

Abstract

Hypertensive crises have been provoked in pheochromocytoma patients by the injection of contrast media during angiography and venography. Fear of similar reactions to intravenous urographic contrast medium injection during computed tomography has led to studies without contrast enhancement when pheochromocytoma is suspected. With extraadrenal pheochromocytomas, intravenous contrast enhancement may be essential for tumor location by computed tomography. The catecholamine responses to injection of urographic contrast medium were examined in eight patients with pheochromocytoma and in 12 undergoing computed tomography for other reasons. Plasma norepinephrine concentrations fell in nonpheochromocytoma patients (p less than 0.005), while in pheochromocytoma patients the response was unpredictable, rising in six individuals, although the mean response was not significant (p greater than 0.35). In five patients the magnitude of the increase in norepinephrine concentrations was large enough to have led to a pressor effect had alpha adrenergic blockade not been used. It was concluded that intravenous urographic contrast medium may elevate plasma catecholamines in a significant proportion of patients with pheochromocytoma, but that with adequate alpha adrenergic blockade this should pose no threat.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610328     DOI: 10.2214/ajr.143.1.43

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

Review 1.  Pheochromocytoma as an endocrine emergency.

Authors:  Frederieke M Brouwers; Jacques W M Lenders; Graeme Eisenhofer; Karel Pacak
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

2.  Hypertensive crisis due to contrast-enhanced computed tomography in a patient with malignant pheochromocytoma.

Authors:  Sachiko Nakano; Yoshito Tsushima; Ayako Taketomi-Takahashi; Tetsuya Higuchi; Makoto Amanuma; Noboru Oriuchi; Keigo Endo
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

Review 3.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Pheochromocytoma presenting as musculoskeletal pain from bone metastases.

Authors:  M D Lynn; E M Braunstein; B Shapiro
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

5.  Cerebrovascular manifestations of pheochromocytoma and the implications of a missed diagnosis.

Authors:  Tamara Majic; Venkatesh Aiyagari
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

6.  A rare and life-threatening cause of pseudo-obstruction in two surgical patients.

Authors:  A C de Lloyd; S Munigoti; J S Davies; D Scott-Coombes
Journal:  BMJ Case Rep       Date:  2010-11-23

7.  Thyrotoxic and pheochromocytoma multisystem crisis: a case report.

Authors:  Kodai Suzuki; Takahito Miyake; Hideshi Okada; Fuminori Yamaji; Yuichiro Kitagawa; Tetsuya Fukuta; Ryu Yasuda; Yoshihito Tanaka; Haruka Okamoto; Sho Nachi; Tomoaki Doi; Takahiro Yoshida; Keisuke Kumada; Shozo Yoshida; Hiroaki Ushikoshi; Izumi Toyoda; Shinji Ogura
Journal:  J Med Case Rep       Date:  2017-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.